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Erythromycin A is a potent antibiotic long-recognized
as a therapeutic option for bacterial infections. The
soil-dwelling bacterium Saccharopolyspora eryth-
raea natively produces erythromycin A from a 55 kb
gene cluster composed of three large polyketide syn-
thase genes (each 10 kb) and 17 additional genes
responsible for deoxysugar biosynthesis, macrolide
tailoring, and resistance. In this study, the erythro-
mycin A gene cluster was systematically transferred
from S. erythraea to E. coli for reconstituted biosyn-
thesis, with titers reaching 10 mg/l. Polyketide
biosynthesis was then modified to allow the produc-
tion of two erythromycin analogs. Success estab-
lishes E. coli as a viable option for the heterologous
production of erythromycin A and more broadly as
a platform for the directed production of erythro-
mycin analogs.
INTRODUCTION
Erythromycin is an established antibiotic effective against
a broad spectrum of Gram-positive bacterial pathogens and is
natively produced from the soil-dwelling bacterium Saccharopo-
lyspora erythraea (Schonfeld and Kirst, 2002). The genes respon-
sible for erythromycin are found clustered within the S. erythraea
chromosome (Cortes et al., 1990; Donadio et al., 1991; Oliynyk
et al., 2007; Summers et al., 1997) and can be further subdivided
into those responsible for (1) formation of the molecule’s
polyketide core, termed 6-deoxyerythronolide B (6dEB); (2)
deoxysugar biosynthesis and attachment; and (3) additional
tailoring and self-resistance (Figures 1A and 1B; see Figure S1
available online). Naturally produced erythromycin includes
a number of variants, with erythromycin A being the most abun-
dant and biologically active form (Figure 1B) (Kibwage et al.,
1985; Majer et al., 1977).
The slow-growing, fastidious nature of S. erythraea coupled to
the lack of sophisticated molecular biology protocols has
hampered more directed efforts to either overproduce or alter
erythromycin A biosynthesis. The situation spurred an interest
in heterologous biosynthesis throughmore technically amenable1232 Chemistry & Biology 17, 1232–1240, November 24, 2010 ª2010microbial systems. Successful heterologous production would
require coordinated expression of a minimum of 20 genes,
including 2 cytochrome P450 monooxygenases and 3 type I
modular polyketide synthase genes that encode for a large
(2 MDa) a2b2g2 multi-domain enzyme complex requiring
40-phosphopantetheine posttranslational modification. The
collective polyketide synthase is referred to as deoxyerythrono-
lide B synthase (DEBS) and is composed of the DEBS1, 2, and 3
enzymes (Figure 1B). Furthermore, the system requires (2S)-
methylmalonyl-CoA and propionyl-CoA substrates that may
prompt separate metabolic engineering of the heterologous
host to support eventual biosynthesis. Thus, the erythromycin
case poses nearly every challenge that must be addressed in
the quest for heterologous complex natural product biosyn-
thesis. Erythromycin A was also particularly attractive because
of the numerous opportunities to influence final compound
structure through manipulation of either polyketide or tailoring
biosynthesis. Supporting this view were the successful semisyn-
thetic erythromycin analogs that extended the molecule’s utility
in the face of acquired pathogenic drug resistance (Denis
et al., 1999; Ma et al., 2001). Heterologous biosynthesis provides
an even greater opportunity for molecular diversification
because the modular polyketide scheme offers seemingly limit-
less options to reprogram biosynthesis for analog formation
(McDaniel et al., 1999).
Despite advances using S. erythraea or Streptomyces strains
(Jacobsen et al., 1997; Kao et al., 1994; Xue et al., 1999), the
knowledge base, molecular biology protocols, and growth
kinetics of E. coli offered even greater potential in terms of
heterologous biosynthesis. More broadly, the last 10–15 years
have seen a growing commitment to the use of heterologous
biosynthesis toward the production of antibiotic or similarly
therapeutic natural products (Zhang et al., 2011). By engineering
for substrate provision, DEBS posttranslational modification and
activity, and coordinated gene expression, 6dEB production
through E. coli was accomplished (Pfeifer et al., 2001). Efforts
then began toward full biosynthesis using an analogous gene
cluster fromMicromonospora megalomicea or a hybrid pathway
composed of genes from S. erythraea, S. fradiae, and S. vene-
zuelae, which produced the intermediates erythromycin C and
6-deoxyerythromycin D, respectively (Lee and Khosla, 2007;
Peiru et al., 2005).
These previous heterologous attempts with E. coli, while
demonstrating the range of molecular biology optionsElsevier Ltd All rights reserved
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Figure 1. Heterologous E. coli Erythromycin A and Analog Production
(A) The erythromycin A gene cluster as organized in the S. erythraea chromosome.
(B) Simplified erythromycin A E. coli biosynthesis scheme including SDS-PAGE analysis of the tailoring biosynthetic enzymes. The Sfp enzyme is required for
posttranslational modification of the DEBS1, 2, and 3 polyketide synthase enzymes; whereas, PrpE (propionyl-CoA synthetase) and PCC (propionyl-CoA carbox-
ylase, composed of two protein subunits) are required to convert exogenous propionate to the starting precursors propionyl-CoA and (2S)-methylmalonyl-CoA
(Pfeifer et al., 2001). Conversion of the 6dEB molecule to erythromycin A is accomplished by the deoxysugar biosynthesis and attachment, additional tailoring,
and self-resistance enzymes (collectively referred to as the tailoring enzymes). The solid arrows present the expected preferred pathway from erythromycin D to
erythromycin A (Lambalot et al., 1995; Paulus et al., 1990). Those genes (eryBI, eryBIII, eryBVII, eryCIV) expressed from pET28a have been denoted with an
asterisk. The remaining genes were expressed from pET21c. M-protein marker; C-BL21(DE3) cellular lysate control; ErmE-erythromycin self-resistance enzyme.
(C) The polyketide and erythromycin analogs resulting from the indicated modifications to the DEBS1 and DEBS3 polyketide synthase enzymes.
See also Figure S1.
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E. coli-Derived Erythromycin and Designed Analogsassociated with the new host, have thus far failed to produce
the most bioactive final form of erythromycin, erythromycin A.
Here, we report the directed production of erythromycin A
through the systematic reconstitution of the S. erythraea biosyn-
thetic pathway in E. coli. The effort required the heterologous
transfer of >50 kb of DNA and the coordinated expression of
26 genes, 23 of which were foreign. In addition, the erythromycin
A modular polyketide biosynthetic scheme was altered to
produce two rationally designed analogs. The results establish
erythromycin A production using E. coli as a heterologous
host and support future applied studies to continually modify
the erythromycin biosynthetic pathway for new antibiotic
compounds and activity.Chemistry & Biology 17, 1232–124RESULTS AND DISCUSSION
Tailoring Biosynthetic Gene Isolation and Individual
Expression
We first used PCR to isolate the tailoring biosynthetic genes
using S. erythraea chromosomal DNA as a template. Each
gene was then placed into separate pET21c vectors to test indi-
vidual gene expression. Although most genes expressed from
pET21c (as assessed by SDS-PAGE) (Figure 1B), four proteins
(EryBI, EryBIII, EryBVII, and EryCIV) were not observed when
gene expression was induced from this vector. However, eryBI,
eryBIII, eryBVII, and eryCIV were successfully expressed from
pET28a. The pET28a vector includes an N-terminal sequence0, November 24, 2010 ª2010 Elsevier Ltd All rights reserved 1233
His-tag sequence
Erythromycin tailoring and resistance genes
lac operator
T7 promoter
T7 terminator
Kanamycin resistance gene
Ampicillin resistance gene
eryBI BII    BIII   BIV   BV   BVI   BVII ermE eryCI CII   CIII   CIV  CV   CVI  eryF eryG eryK
pHZT1 pHZT2
Figure 2. Operon Design for the pHZT1 and pHZT2 Plasmids
See also Figure S3.
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E. coli-Derived Erythromycin and Designed Analogs(containing a 63 histidine tag) preceding the original start codon
of the gene to be expressed, and this addition may account for
the positive impact upon final protein production. Convenient
biosynthetic or phenotypic tests were then performed to confirm
the activity of select enzymes. Specifically, eryF expression al-
lowed conversion of 6dEB to erythronolide B, and ermE expres-
sion provided resistance to erythromycin (Figure S2). Because
most polyketide products (including erythromycin A) derive
from hosts exhibiting a high G+C genetic content, alternative
approaches to improving expression have included designed
gene synthesis to eliminate rare codon usage within a new
host or commercially available hosts designed to accommodate
G+C rich genes (Gouy and Gautier, 1982; Menzella et al., 2006).
However, our system relied totally on the original gene
sequences from S. erythraea and highlighted the native capabil-
ities of E. coli, at least in this case, to accommodate significantly
foreign genes and proteins. In addition, our approach was in
contrast to earlier efforts, which used a combination of
tailoring genes from multiple sources (S. erythraea, S. fradiae,
and S. venezuelae) that each demonstrated sufficient heterolo-
gous expression within E. coli (Lee and Khosla, 2007). Here,
we were able to directly reconstitute full activity from the original
S. erythraea erythromycin A pathway.
Tailoring Biosynthetic Operon Design
With successful individual gene expression confirmed, our atten-
tion turned to packaging the tailoring and resistance genes for
transfer to and coordinated expression within E. coli. Operons
were designed using a strategy similar to earlier efforts at
introducing modular polyketide and nonribosomal peptide path-
ways to heterologous hosts (Kao et al., 1994; Lee and Khosla,
2007; Peiru et al., 2005; Pfeifer et al., 2001, 2003; Watanabe
et al., 2006). Namely, synthetic operons were constructed
according to the diagram in Figure 2 (a more detailed diagram
is provided in Figure S3). Here, the cassettes demonstrating
successful individual expression were used to construct two
operons of eight and nine genes with each operon driven by
a preceding T7 promoter under the control of a lac operator. It
should be noted that no specific biosynthetic activity has been
assigned to EryBI, and the removal of eryBI has been shown to
have negligible effect on native S. erythraea erythromycin A pro-
duction (Gaisser et al., 1998). However, here, eryBIwas included
so as to retain any resulting beneficial activity within a heterolo-
gous environment. The ermE self-resistance gene was similarly
included to protect the E. coli host from nascent erythromycin
A activity. The final operons were subsequently used in the
following experiments to generate E. coli-derived erythromycin
A, and coordinated gene expression and enzymatic activity
were confirmed in the context of those experiments.
E. coli Growth Phenotype and Plasmid Stability
when Including the Tailoring Biosynthetic Operons
To characterize cell growth with the inclusion of the tailor-
ing biosynthetic operons, strain BL21(DE3)(pHZT1/pHZT2)
(including pGro7; please see below) was compared under
different growth conditions (Figure S3). No obvious differences
were observed with or without induction, implying that the
tailoring plasmids were not overly burdensome to the cell during
gene expression. However, as previously observed for those1234 Chemistry & Biology 17, 1232–1240, November 24, 2010 ª2010plasmids harboring the DEBS genes (Pfeifer et al., 2001),
plasmid instability was apparent for pHZT1 (61% retention
12 hr after induction) and pHZT2 (28% retention 12 hr after
induction). This no doubt stems from both plasmids containing
the same origin of replication, further supported by the 100%
retention of pGro7 containing a different, compatible origin.
E. coli-Derived Erythromycin A Biosynthesis
Initial efforts at E. coli erythromycin A biosynthesis consisted of
producing 6dEB from a strain containing the required DEBS1,
2, and 3 enzymes followed by feeding the extracted 6dEB
product to a separate E. coli strain containing the plasmids
harboring the newly constructed tailoring biosynthetic operons.
No production was observed under these conditions. However,
when plasmid pGro7 containing the genes for the E. coli GroEL/
ES chaperone system was introduced to the strain containing
the tailoring biosynthetic operons, production of erythromycin
B and D was observed by LC-MS analysis (Figure S4). Similar
approaches to aid protein folding and/or association have
been needed during previous complex natural product biosyn-
thetic attempts (Betancor et al., 2008; Lee and Khosla, 2007;
Mutka et al., 2006; Peiru et al., 2005; Pfeifer et al., 2001), further
highlighting the challenges associated with reconstituting
such pathways. In this case, the accumulation of erythromycin
B suggested to us that biosynthesis might be stalled at the
step where the EryK P450 hydroxylase converts erythromycin
D to erythromycin C (Figure 1B).
Given this status, we analyzed the positioning of eryK in our
operon design. The eryK gene was the last of nine genes in
one of the tailoring operons. As such, we hypothesized a lack
of gene expression and supplemented expression by adding
another plasmid expressing only eryK. This addition resulted in
erythromycin C and A production at 2 and 10 mg/l, respectively,
with 90% of the erythromycin product secreted to the
surrounding medium; the erythromycin extract was further
characterized by MS/MS analysis, and antibiotic activity was
confirmed through a separate Bacillus subtilis growth inhibition
assay (Figure 3; Figure S5). The initial erythromycin A titer is
considered promising given the metabolic and process engi-
neering tools available for E. coli. For example, E. coli fed-batch
bioreactor protocols have previously been used to overproduce
the 6dEB precursor to titers >1 g/l, a nearly 200-fold increase
over original levels (Lau et al., 2004).
In an effort to consolidate the entire erythromycin A biosyn-
thetic pathway to a single E. coli cell, we altered the resistance
markers of the plasmids responsible for 6dEB biosynthesis
such that one cell harbored all six plasmids required for bothElsevier Ltd All rights reserved
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Figure 3. Confirmation of E. coli Erythromycin A Production from the Serial, Two-Cell Scheme
(A) Chromatogram and mass spectrum for erythromycin A standard.
(B) Chromatogram and mass spectrum for E. coli-derived erythromycin A.
(C) Final titer quantification (± standard deviation; N = 3).
See also Figure S5.
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Figure 4. Erythromycin Analog 2 Production and Quantification
The mass spectra for E. coli-derived (A) 1 (457 m/z; sodium adduct) and (B) 2 (752 m/z) produced from the serial, two-cell scheme using BAP1(pBP130/pBP165)
followed by BL21(DE3)(pHZT1/pHZT2/pHZT4/pGro7). The higher m/z peaks observed most likely represent co-eluting contaminants extracted from production
medium or dimerized erythronolide products.
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E. coli-Derived Erythromycin and Designed Analogspolyketide and tailoring biosynthesis. Doing so resulted in eryth-
romycin A production at 0.6 mg/l (Figure S6), and even though
the final titer was reduced when compared to the sequential
production strategy, one-cell production confirmed the capa-
bility of E. coli to coordinately express the 26 genes required
for final erythromycin A biosynthesis from an inexpensive
three-carbon building block of propionate.
Erythromycin Analog Design and Biosynthesis
We next sought to extend the E. coli erythromycin production
platform toward analog biosynthesis. As illustrated in Figure 1C,
variations were made to the DEBS1 and DEBS3 enzymes in an
effort to leverage the multi-catalytic capability of the modular
polyketide synthase. Specifically, the loading module of
DEBS1 was replaced with the loading module from the rifamycin
polyketide synthase such that a benzoate starter unit could be
accepted, producing a benzyl addition to the erythromycin1236 Chemistry & Biology 17, 1232–1240, November 24, 2010 ª2010structure (Admiraal et al., 2001; Pfeifer et al., 2001). Similarly,
the second module of DEBS3 was altered to accept a malonyl-
CoA extender unit, which would result in the lack of a methyl
group at the C2 position when compared to the original erythro-
mycin A compound (Liu et al., 1997). In this way, analogs of 6dEB
and, subsequently, erythromycin were expected.
Figures 1C, 4, and 5 summarize the analogs produced by
this approach. Compound 2, an analog of erythromycin D with
a designed benzyl unit, was produced at a titer of 0.49 ± 0.19
(standard deviation) mg/l; analog 4 was generated together
with its corresponding B, C, and D derivatives at titers between
0.05 and 0.2 mg/l. For all erythromycin A and analog heterolo-
gous production experiments, intermediates such as erythrono-
lide B and 3-mycarosyl-erythronolide B (or their corresponding
analog equivalents) were also observed during final LC-MS
analyses (Figure S1). We believe compound 2 results from the
benzyl group hindering the activity of EryK. This would thenElsevier Ltd All rights reserved
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Figure 5. Erythromycin Analog 4 Production and Quantification
The mass spectra for E. coli-derived (A) 3 (395 m/z; sodium adduct) and (B) 4 (720 m/z) produced from the serial, two-cell scheme using BAP1(pBP144/pBP173)
followed by BL21(DE3)(pHZT1/pHZT2/pHZT4/pGro7).
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E. coli-Derived Erythromycin and Designed Analogsexplain the lack of B, C, and A analog equivalents for compound
2 because the preferred pathway for biosynthesis begins with
the activity of EryK. Interestingly, erythromycin A was also
observed from the experiments to produce compounds 2 and
4. For the case of compound 2, this unexpected result could
be explained by propionyl-CoA being loaded directly to the
ketosynthase domain of DEBS1 (Long et al., 2002; Pereda
et al., 1998; Weissman et al., 1998); however, for compound 4,
the reasons for erythromycin A coproduction are unclear. Finally,
we note that analog production demonstrates a level of flexibility
associated with the glycosyltransferase enzymes responsible
for attaching the deoxysugar residues to the macrolactone
polyketide core. This flexibility has been observed with other
systems and identified as a key step in realizing the full potential
of altered structural design (Borisova et al., 2006). Success in this
case supports the capabilities of the native glycosyltransferase
enzymes to accommodate similar modifications to the polyke-
tide and tailoring steps anticipated in analog biosynthetic
approaches.Chemistry & Biology 17, 1232–124In summary we present the complete biosynthesis of erythro-
mycin A using E. coli as a heterologous host. Besides providing
access to the most potent form of erythromycin, the E. coli
productionplatformoffersnumerousnext-generationengineering
opportunities. Optimal protein levels and activity, availability of
required cofactors and precursors, conversion of substrate to
product, and scaled bioreactor production are just of a few of
the challenges to be addressed with the established engineering
tools available to E. coli. Aiding this effort will be the range of
molecular biology strategies to manipulate native and heterolo-
gous metabolism. These same molecular engineering strategies
will also offer extended erythromycin analog design and have
been used here for the directed production of compounds 2 and
4. However, themodular, multi-catalytic nature of the DEBS poly-
ketidesynthase, in addition to theengineeringopportunitieswithin
tailoring biosynthesis, promises awide range of newcompounds.
This potential then stands as an answer to the need for new
antibiotics to combat the growing presence of pathogenic drug
resistance (Fischbach and Walsh, 2009; Walsh, 2003).0, November 24, 2010 ª2010 Elsevier Ltd All rights reserved 1237
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There is no doubt about the positive impact antibiotics and
other natural products have had on modern medicine.
However, beneath this medicinal value lie the technical
challenges of ready access to complex natural compounds.
Production from intractable environmental sources limits
the speed, economy, and structural diversity possible from
reconstituted biosynthesis in technically convenient heter-
ologous hosts. Thus, heterologous biosynthesis offers the
potential of rapid overproduction of original and analog
forms of clinically relevant natural compounds. This report
presents the complete production of erythromycin A using
E. coli as a heterologous host. The work is significant for
several reasons: (1) erythromycin A is an established antibi-
otic compound with a complex polyketide biosynthetic
pathway; (2) the full heterologous production of this com-
pound has not been reported, and the steps to do so re-
quired overcoming several challenges in heterologous
gene transfer, coordinated gene expression, metabolic
engineering, and final biosynthetic activity; (3) unoptimized
product titers have reached 10 mg/l, a starting point
considered promising given the range of metabolic and
process-engineering options associated with E. coli; and
(4) two designed analogs were produced through directed
manipulation of polyketide biosynthesis; subsequent efforts
offer the promise of generating a range of new bioactive
analogs. The last point is of particular relevance given the
balance between bacterial drug resistance to erythromycin
(and other antibiotics) and the compound’s modular biosyn-
thetic pathway. Thus, successful reconstitution through
E. coli offers an alternative route to the original compound
and a platform for full manipulation of the biosynthetic
pathway with the express purpose of expanding molecular
diversity and antibiotic activity.
EXPERIMENTAL PROCEDURES
Reagents and Chemicals
The reagents and chemicals used in this study were purchased from Fisher
Scientific (Pittsburgh, PA, USA) or Sigma (St. Louis, MO, USA). All restriction
enzymes and the Phusion High-Fidelity PCR Master Mix were purchased
fromNew England Biolabs (Ipswich, MA, USA). PCR primers were synthesized
byOperon (Huntsville, AL, USA). The chaperone plasmid kit and the pCDFDuet
vector were purchased from Takara (Madison, WI, USA) and EMD Chemicals
Inc. (Gibbstown, NJ, USA), respectively.
Cell Culture Media and Growth Conditions
All E. coli cell cultures for molecular biology and SDS-PAGE analysis were
conducted in Luria-Bertani (LB) medium at 37C and 250 rpm. Heterologous
6dEB and erythromycin biosynthesis were conducted in production medium
at 22C and 250 rpm. One liter of production medium contained 5 g yeast
extract, 10 g tryptone, 15 g glycerol, 10 g sodium chloride, 3 ml 50% v/v
Antifoam B, 100 mM 4-(2-hydroxyethyl)-1-piperazineethanesuffonic acid
(HEPES) buffer, and was adjusted to pH 7.6 by 5 M NaOH before use.
Plasmid Design, Construction, and Gene Expression
Restriction enzyme digestions, SDS-PAGE, and other standard molecular
biology techniques were performed as described by Sambrook et al. (1989).
Erythromycin-tailoring and resistance genes were PCR amplified from
S. erythraea genomic DNA using the primers listed in Table S1. The NdeI/EcoRI
digested fragments of the PCRproducts (except for genes eryBIII,BV, andCIII)1238 Chemistry & Biology 17, 1232–1240, November 24, 2010 ª2010were individually inserted into plasmid pET21c digested with the same restric-
tion enzymes. The eryBIII PCR product was digested by NheI/EcoRI and
inserted into pET21c using the corresponding restriction sites. Similarly, the
eryBV and eryCIII PCR products were digested and inserted by NdeI/SacI
and NdeI/HindIII, respectively. After transformation of the individual pET21c
expression cassettes into BL21(DE3), cultures were induced overnight at
37C, followed by sonication cell disruption. Cell lysates were clarified by
centrifugation, and soluble fractions were analyzed by SDS-PAGE.
The tailoring genes that could not be expressed using pET21c (eryBI, BIII,
BVII, and CIV) were transferred to plasmid pET28a by NheI/HindIII (for eryBIII)
or NdeI/HindIII (for eryBI, BVII, and CIV) digestion and subsequent ligation.
SDS-PAGE was performed as previously described to investigate expression
from pET28a. The insertion of all erythromycin tailoring and resistance genes
into individual expression plasmids was verified by Sanger sequencing at
the Tufts University Core Facility.
After SDS-PAGE confirmation of gene expression, the eryBI, BII, BIII, BIV,
BV, BVI, BVII, and ermE genes were combined (in order) into one operon by
sequential XbaI/SpeI and SacI digestion and ligation (Figure S3). The resulting
plasmid pHZT1 was a derivative of the kanamycin-resistant pET28a plasmid.
Genes eryCI, CII, CIII, CIV, CV, CVI, eryF, eryG, and eryK were combined
(in order) into one operon by sequential XbaI/SpeI and HindIII digestion and
ligation. The resulting plasmid pHZT2 was a derivative of the ampicillin-resis-
tant pET21c plasmid.
In order to construct a plasmid carrying an additional eryK gene, PCR and
PstI/HindIII digestion preceded ligation into the streptomycin-resistant
pCDFDuet-1 vector. The resulting plasmid was named pHZT4. In addition
the chaperone expression plasmids pG-KJE8, pGro7, pKJE7, pG-Tf2, and
pTf16 were individually co-transformed with plasmids pHZT1, pHZT2, and
(when indicated) pHZT4 into E. coli BL21(DE3) to test the effects each chap-
erone or chaperone combination had on erythromycin biosynthesis.
For one-cell production of erythromycin A, plasmid pBP130 containing the
genes for DEBS2 and DEBS3 (Pfeifer et al., 2001) was modified by replacing
the ampicillin-resistance marker with an apramycin (apr)-resistance marker
though l-Red recombination (Datsenko and Wanner, 2000). Specifically, the
apr-resistance gene was PCR amplified using plasmid pSBAC as a template
(Liu et al., 2009) (Table S1). Purified PCR product and plasmid pBP130 were
co-transformed into E. coli TOP10 harboring pKD46 (Datsenko and Wanner,
2000) through electroporation, and the resulting culture was grown in LB
medium overnight at 37C. Plasmid product was then isolated from the over-
night culture and transformed into E. coli TOP10 for selection on an LB-agar
plate containing 50 mg/l apr. Positive colonies were cultured and the resulting
plasmids assessed by restriction analysis. The final plasmid was named
pBPJW130.
In a similar fashion the kanamycin resistance marker on plasmid pBP144
(containing the genes required for the PCC and DEBS1; Pfeifer et al., [2001])
was changed to a tetracycline resistance marker. Here, the tetracycline-
resistance gene was PCR amplified from plasmid pBR322 (Table S1). The
kanamycin marker of pBP144 was replaced analogous to the procedure to
modify pBP130, and the resulting plasmid was named pBPJW144.
For analog production, plasmids pBP165 (kanamycin resistant) and pBP173
(ampicillin resistant) were introduced to replace pBP144 and pBP130,
respectively. Plasmid BP165 was described previously (Pfeifer et al., 2001)
and contains the rifamycin-loading di-domain instead of the native DEBS1
di-domain. Plasmid BP173 derives from the constructs presented in Liu
et al. (1997), in which the acyltransferase domain of module 6 is replaced
with the rapamycin module 2 acyltransferase such that the extender unit
accepted at this position is malonyl-CoA.
Erythromycin Biosynthesis and Analysis
For serial, two-cell erythromycin production, 6dEB was first generated using
strain BAP1(pBP130/pBP144) as previously described (Zhang et al., 2010).
For 6dEB analog 3, BAP1(pBP173/pBP144) was cultured in 100 ml production
medium containing 100 mg/l carbenicillin, 50 mg/l kanamycin, 100 mM iso-
propyl b-D-1-thiogalactopyranoside (IPTG), and 20 mM propionate at 22C
for 7 days. Analog 1 was produced similarly (Pfeifer et al., 2001) from BAP1
(pBP130/pBP165) with 20 mM of benzoate (stock solution adjusted to pH 7)
included with the propionate, IPTG, and selection antibiotics. Native 6dEB
and both analogs were extracted with ethyl acetate, dried, and resuspendedElsevier Ltd All rights reserved
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Light Scattering Detector, and the 6dEB analogs were quantified by MS as
previously described (with purified 6dEB as a standard) (Zhang et al., 2010).
To complete the two-cell production process, an overnight culture of E. coli
BL21(DE3)(pHZT1/pHZT2/pHZT4/pGro7) was inoculated (5% v/v) into 1 ml
production medium containing 100 mg/l carbenicillin, 50 mg/l kanamycin,
20 mg/l chloramphenicol, 50 mg/l streptomycin, 100 mM IPTG, and 2 mg/ml
arabinose (pGro7 required arabinose induction) and cultured at 22C for
24 hr. The 6dEB or 6dEB analog methanol extracts (produced as described
in the preceding paragraph) were then added to final polyketide concentra-
tions of 50 mg/l, and erythromycin production commenced by culturing for
an additional 3 days at 22C.
For one-cell erythromycin A production, an overnight culture of E. coli
BAP1(pBPJW130/pBPJW144/pHZT1/pHZT2/pHZT4/pGro7) was inoculated
(5% v/v) into 1 ml production medium containing 100 mg/l carbenicillin,
50 mg/l kanamycin, 20 mg/l chloramphenicol, 50 mg/l streptomycin,
50 mg/l apr, 5 mg/l tetracycline, 100 mM IPTG, 2 mg/ml arabinose, and
20 mM propionate and grown at 22C for 7 days.
One milliliter of the E. coli cultures containing erythromycin A or the erythro-
mycin analogs was extracted with 0.5 ml ethyl acetate. After centrifugation at
12,000 rpm for 1 min, the extract was transferred to a 1.5 ml micro-centrifuge
tube, air dried, and resuspended in 100 ml of methanol. Samples were
then analyzed using an LTQ XL Linear Ion Trap Mass Spectrometer (Thermo
Electron Corporation) coupled with a Finnigan Surveyor LC system (Thermo
Electron Corporation) with an Agilent ZORBAX Eclipse XDB-C18 HPLC
column (Santa Clara, CA, USA). All MS analyses used electrospray ionization
and were conducted in positive ion mode. A linear gradient of 100% water to
100% acetonitrile over 15 min was used at a flow rate of 0.6 ml/min. Where
indicated, MS/MS analysis was performed using a collision energy of 25 V.
To quantify erythromycin A and analog production, an LC-MS calibration
curvewaspreparedusing commercially available erythromycinAas anexternal
standard and roxithromycin as an internal standard. Known amounts of
erythromycin A were added to E. coliBL21(DE3) or BAP1 cultures grown under
the same conditions described above. After ethyl acetate extraction, the
sampleswere dissolved in 100ml ofmethanol containing 2.5mg/l roxithromycin
and subjected to LC-MS analysis to prepare the calibration curve. A portion of
the extracts resulting from the erythromycin producing E. coli cultures was
similarly mixed with roxithromycin and analyzed against the calibration curve.
The ratio of the erythromycin A and roxithromycin standard peak areas was
correlated with erythromycin A concentrations to quantify experimental
erythromycin production with a suitable calibration curve made before every
experimental analysis. All reported titers represent at least three independent
experiments. Negative controls included (1) experiments reliant on strain
BAP1 without the required production plasmids, (2) uninduced cultures, and
(3) the replacement of pHZT2 with an empty pET21c expression vector.
Bacillus subtilis Growth Inhibition Bioassay
To confirm the antibiotic activity of E. coli-derived erythromycin A, a B. subtilis
zone-of-inhibition bioassay was performed. Methanol solutions of erythro-
mycin extracts were adjusted to specific concentrations based upon the
results from quantification. This solution was then added to a filter paper
disk and placed upon an LB agar plate prepared bymixing 20 ml of an overnight
B. subtilis culture with 20 ml liquified LB agar (maintained at 45C). After
overnight incubation at 37C, B. subtilis inhibition zones were assessed for
positive control, negative control, and experimental filter disk samples. The
assay was repeated a minimum of three times from independent culture
experiments to ensure reproducibility.
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